March 15, 2020
How do pharmaceutical companies profit from COVID-19? (do they?)
How do pharmaceutical companies prophet from COVID-19? Do they make the profit?
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Enanta Pharmaceuticals
September 25, 2019
Enanta’s study meets goal for its lead FXR agonist, EDP-305, for the treatment of NASH
Enanta’s study has met its primary endpoint, as ALT reduction at week 12, was met in the 2.5mg dosing group in testing its lead FXR agonist, EDP-305 for treatment of NASH, also meeting key secondary endpoint, reduction in liver fat content as measured by MRI-PDFF at week 12, in the 2.5mg dosing group.
March 27, 2019
Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress™ 2019
New preclinical data to be presented on Core inhibitor EDP-514 targeting HBV FXR agonist EDP-305 targeting NASH ASK-1 inhibitors EP-026856…
March 18, 2019
Enanta Pharmaceuticals Completes Enrollment in Two Ongoing Phase 2 Studies
Respiratory Syncytial Virus (RSV) Human Challenge Study with EDP-938 ARGON-1 Study in Non-alcoholic Steatohepatitis (NASH) with EDP-305 WATERTOWN, Mass.–(BUSINESS WIRE)–lt;a…